INVO Fertility Q2 2025 revenue up 1% to record $1.86M, net loss widens to $3.2M

INVO Fertility, Inc.

2025-Q2 EPS reported -$75.85 revenue$3,500,839

Q2 2025 revenue $1,863,654 (record), up 1% YoY; clinic revenue $1,832,094 up 1%.
Net loss from continuing operations $(3.2)M vs $(2.2)M in Q2 2024.
Adjusted EBITDA $(587,230) vs $(509,623) in prior year period.
Completed divestiture of majority stake in NAYA Therapeutics; retains minority position.
Launched telehealth and PRP therapy at Wisconsin clinic; received patent allowance for INVOcell device through 2040.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.